Lu-Ping Li1, JoAnn Carbray1, Maria Papadopulou-Rosenzweig2, Richard Solomon3, Pottumarthi V. Prasad1
1Radiology, Northshore University Healthsystem, Evanston, IL, United States; 2Radiation Medicine, Northshore University Healthsystem, Evanston, IL, United States; 3Nephrology, University of Vermont, Burlington, Burlington, VT, United States
Radiocontrast nephropathy (RCN) is the 3rd common cause of in-hospital mortality in patients with pre-existing kidney insufficiency. Although low- and iso-osmolal radiocontrast are in general believed to be safer than older ionic and high-osmolal agents, the issue remains controversial. Renal hypoxia plays a role in the pathophysiology of RCN and BOLD MRI was previously shown to be useful in monitoring the changes in intra-renal oxygenation with iothalamate, a 1st generation ionic high osmolality agent. Here, we report our preliminary findings using iodixanol, a 3rd generation nonionic iso-osmolality agent, that suggest similar trends as reported earlier with iothalamate.